TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01577823

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter
Study: NCT04850807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music & Memory
Description: Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences at times when behaviors are likely
Study: NCT05108831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePOCT+
Description: ePOCT+ is an electronic clinical decision support algorithm
Study: NCT05759923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OATD-02
Description: Boin Design Scheme will be applied for dose escalation. Dose will start with 2.5mg o.d., the desicion about dose escalations will be made based on the occurence of DLT
Study: NCT06775314

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream combination
Description: placebo cream combination will be given to subjects to be applied every morning, evening and night in group 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo spot cream
Description: placebo spot cream will be given to subjects to be applied every morning and evening in group 1
Study: NCT06777628

Intervention type: DRUG
Intervention: Immunochemotherapy combined with antiangiogenic
Description: Immunochemotherapy combined with antiangiogenic
Study: NCT06061965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based resilience-building intervention
Description: There are 6 modules on the website. Participants will be encouraged to verbalize their impressions of the website prototype.
Study: NCT04590261

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Peripheral Blood sampling, 25 mL

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Peripheral Blood sampling, 25 mL

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Peripheral Blood sampling, 25 mL

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Peripheral Blood sampling, 25 mL

Intervention type: OTHER
Group type: OTHER
Intervention: Nasal Brushing
Description: Nasal Brushing, facultative

Intervention type: OTHER
Group type: OTHER
Intervention: Nasal Brushing
Description: Nasal Brushing, facultative

Intervention type: OTHER
Group type: OTHER
Intervention: Nasal Brushing
Description: Nasal Brushing, facultative

Intervention type: OTHER
Group type: OTHER
Intervention: Nasal Brushing
Description: Nasal Brushing, facultative
Study: NCT04488289

Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle
Description: Cardiovascular risk and lifestyle
Study: NCT06085079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab Prefilled Syringe
Description: Ixekizumab is a humanized IgG4 monoclonal antibody that binds with high affinity and specificity to IL-17A. This medication is currently approved for the treatment of plaque Ps, ankylosing spondylitis, and psoriatic arthritis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab Prefilled Syringe
Description: Ixekizumab is a humanized IgG4 monoclonal antibody that binds with high affinity and specificity to IL-17A. This medication is currently approved for the treatment of plaque Ps, ankylosing spondylitis, and psoriatic arthritis.
Study: NCT06321419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced Trauma Life Support training
Description: Advanced Trauma Life Support (ATLS) is a proprietary 2.5 day course teaching a standardised approach to trauma patient care using the concepts of a primary and secondary survey. The programme was developed by the Committee of Trauma of the American College of Surgeons. The course includes intial treatment and resuscitation, triage and interfacility transfers. Leaning is based on practical scenario-driven skill stations, lectures and includes a final performance proficiency evaluation. Physicians will be trained in an accredited ATLS training facility in India.
Study: NCT05570565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: ultrasound guided injection of local anesthestics drugs (mixture of lidocaine and bupivacaine) in the Erector spinae plane which lies between the Erector spinae muscle and lumbar transverse process

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local field block
Description: infiltration of local anesthestic drugs( mixture of lidocaine and bupivacaine) in the surgical field before surgical incision
Study: NCT06299033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hNPC01
Description: hNPC01, human forebrain neural progenitor cell product, intracerebral injection
Study: NCT06219057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Wise Adolescent
Description: The program encompasses 20 individual weekly sessions manualized. Its main objective is to help adolescents to create affiliative feelings towards themselves and to develop a more compassionate inner voice. Sessions are organized across 6 main domains: (1) placing ourselves in the challenges of life: evolutionary roots of our mind, how social circumstances and life experiences shape us; the 3-affect regulation systems; (2) understanding difficulties: compassion focused therapy case formulation; (3) understanding compassion: the three flows of compassion, its three pillars (caring commitment, wisdom, strength and courage); (4) compassionate mind training: cultivating the compassion skills (compassionate attention, imagery, reasoning, and behavior); (5) working with difficulties: fears, blocks and resistances to compassion; multiple selves; shame and self-criticism; (6) sustaining a compassionate mind: reviewing the gains and relapse prevention.
Study: NCT06038526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo buccal, nasal, and blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Undergo bronchoscopy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon Monoxide Measurement
Description: Undergo CO testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05413785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth in Parole/Probation Office
Description: Onsite (telehealth) linkage toHep C treatment in a Probation and Parole office setting via an onsite nurse navigator. The navigator will provide Hep C education, draw labs, and facilitate a telemed visit with a UK GI provider.
Study: NCT04484649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleeping Healthy/Living Healthy
Description: Sleeping Healthy/Living Healthy will be a school based health center (SBHC)-based intervention integrating mind-body integrative health (MBIH) and sleep hygiene strategies to improve sleep quality in urban adolescents. The Sleeping Healthy/Living Healthy intervention content and format will be determined in a Development Phase 1. The investigator anticipates the intervention will consist of two group and two one-on-one sessions. The intervention will be grounded in social-cognitive theory and use motivational interviewing to support MBIH and sleep hygiene strategies. Sessions will be delivered once per week by SBHC providers and health educators.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: The Attention Control Intervention condition will meet the requirements for a comparison treatment for testing behavioral interventions - equivalent in contact time, credible and interesting, and exert limited treatment effects.~In the same number of sessions and format as the Sleeping Healthy/Living Healthy intervention (anticipated to be two group and two one-on-one sessions delivered once per week by SBHC providers and health educators), the study will teach participants about sleep and other health topics relevant to adolescents (e.g., nutrition, injury prevention) devoid of the MBIH elements in our integrated intervention.
Study: NCT06450925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: Enrolled subjects will receive one observed oral vitamin A dose, prior to their HSCT, in the outpatient clinic or inpatient Bone Marrow Transplant (BMT) floor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills containing microcrystalline cellulose will be dispensed in patients who are randomized to the placebo arm.
Study: NCT05706155

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Diet
Description: Hypocaloric diet to achieve a 5% weight loss with macronutrient distribution according to current guidelines for T2D: 45 to 55% of energy from carbohydrates, prioritizing those with low glycemic index; 25 to 30% from total fats and a maximum of 10% from saturated fats; 20% of energy from proteins, 15% from animal sources and 5% from plant sources. Participants will also receive printed and validated educational material, with recommendations for healthy eating, and will be instructed to maintain their habitual physical activity level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-based Diet
Description: Hypocaloric diet to achieve a 5% weight loss. The dietary prescription was adapted from the Eat-Lancet Commission report to Brazilian population culture, with 45 to 55% of energy from carbohydrates, prioritizing those with a low glycemic index; 25 to 30% from total fats and a maximum of 5% from saturated fats; 20% from proteins, 5% from animal sources and 15% from plant sources. Participants in this group will receive printed and validated support material with recommendations for a healthy and plant-based eating, and will be instructed to maintain their habitual physical activity level.
Study: NCT06153849

Intervention type: DIAGNOSTIC_TEST
Intervention: urine sample collection
Description: Urine samples from patients receiving BCG instillation was collected for LC-WGS to evaluate CIN and urinary microbiome.
Study: NCT06031428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MANAGe-DM - novel nurse case management
Description: Participants assigned to MANAGe-DM will receive the standard diabetes education mailing in addition to a novel nurse case management intervention. Each month of the study period, the NCM will conduct two phone call intervention sessions with individual participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monthly Educational Mailing
Description: All participants in the study will receive diabetes education mailers. This includes monthly mailings of diabetes education, based off the American Diabetes Association guidelines for Diabetes Education. Topics covered will include diabetes basics, monitoring and medications, healthy eating and exercise, overview of common comorbidities, basics of foot care, and strategies for overcoming common pitfalls.
Study: NCT04909931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D 2
Description: Randomized allocation first arm : add on vitamin D supplementation 40,000 iu/week for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Second arm : add on placebo for 12 weeks
Study: NCT06130449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natesto testosterone intranasal gel
Description: A single dose of Natesto (11 mg total, 5.5 mg per nostril) will be administered to each participant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ayr Saline Nasal Gel
Description: A single dose of Ayr (one spray per nostril) will be administered to each participant.
Study: NCT05788783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery & Care Canine-Assisted Therapy
Description: Active intervention. An 6-week session of structured, goal-oriented activities where youth focus on mastering dog obedience and dog training skills. Each session is 1 hour and 15 minutes in length and includes education, review of prior sessions, and specific skill-building activities. Skill-building activities progress in complexity during the course of the 6-week curriculum.

Intervention type: OTHER
Group type: OTHER
Intervention: Canine Education & Bonding
Description: Active control intervention. An 6-week session of semi-structured activities. Sessions are 45 minutes in length. Youth in this condition engage in an educational component, passive observation of dog-training skills, and an active free-play session with the dog-handler teams.
Study: NCT05851378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG)
Description: Given intravenously at time of imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG)
Description: Given intravenously at time of imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Image (MRI)
Description: Magnetic resonance imaging is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Image (MRI)
Description: Magnetic resonance imaging is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
Study: NCT04959344

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kleb4V target dose
Description: Two doses of the non-adjuvanted Kleb4V target dose will be administered intramuscularly 2 months apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kleb4V target dose + AS03
Description: Two doses of the adjuvanted Kleb4V target dose will be administered intramuscularly 2 months apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kleb4V low dose
Description: Two doses of the non-adjuvanted Kleb4V low dose will be administered intramuscularly 2 months apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kleb4V low dose + AS03
Description: Two doses of the adjuvanted Kleb4V low dose will be administered intramuscularly 2 months apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses of the Placebo will be administered intramuscularly 2 months apart
Study: NCT05076903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OFA
Description: Dexmedetomidine and lidocaine are administered during anesthesia, and opioid is not used. For induction, 1 μg/kg of Dexmedetomidine is administered over 10 minutes and 1mg/kg of lidocaine is administered intavenously (bolus). This is followed by continuous intravenous infusion of dexmedetomidine at a rate of 0.2-0.7 μg/kg/h and infusion of lidocaine at the rate of 1 mg/kg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Remifentanil is infused during anesthesia, and target-controlled infusion (TCI) is performed according to the Minto model. During indcution of anestheisa, target concentration of remifentanil is set within 3-5 ng/mL. After intubation, target concentration is adjusted within the range of 2-8 ng/mL.
Study: NCT06499077

Intervention type: DIAGNOSTIC_TEST
Intervention: Sampling of exhaled breath
Description: Exhaled breath of all participants is collected following our standardized procedure

Intervention type: DIAGNOSTIC_TEST
Intervention: Sampling of exhaled breath
Description: Exhaled breath of all participants is collected following our standardized procedure
Study: NCT04755504

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EEG behind the ear
Description: 2 additional electrodes behind each ear will record EEG
Study: NCT06430424

Intervention type: BIOLOGICAL
Intervention: Relapsed glioblastoma
Description: Paired tumor samples diagnosis/relapse
Study: NCT04877756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLX10010
Description: Lyophilized cake reconstituted with WFI and injected intradermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLX10010
Description: Lyophilized cake reconstituted with WFI and injected intradermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLX10010
Description: Lyophilized cake reconstituted with WFI and injected intradermally
Study: NCT06497699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexycu
Description: single injection,5ul solution,concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone
Study: NCT05064176

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Home physical therapist performs usual care and educates the patient to perform self-management~Usual care:~M1-6: 6 months of maintenance decongestive lymphatic therapy (DLT) (by patient and home physical therapist):~* week 1-2: no physical therapy; patient performs limb elevation, muscle contractions and wears the bandage (intervention group)/ compression garment (control group)~* week 3-4: start physical therapy, 2 days/ week: exercises, skin care \& manual lymph drainage (MLD), education; self-management by patient and wearing compression garment 14-16h/day (4 sessions) M2-6: 1 day/ week physical therapist: exercises, skin care \& MLD, and self-management by patient and wearing compression garment 14-16h/day (20 sessions)~M7-12: 6 months of maintenance DLT by patient (self-management) and home physical therapist:~- 1 day/week physical therapist: skin care, MLD, exercises (26 sessions) Month 13-18: 6 months of maintenance DLT by patient Month 19-36: 18 months of follow-up

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Home physical therapist performs usual care and educates the patient to perform self-management~Usual care:~M1-6: 6 months of maintenance decongestive lymphatic therapy (DLT) (by patient and home physical therapist):~* week 1-2: no physical therapy; patient performs limb elevation, muscle contractions and wears the bandage (intervention group)/ compression garment (control group)~* week 3-4: start physical therapy, 2 days/ week: exercises, skin care \& manual lymph drainage (MLD), education; self-management by patient and wearing compression garment 14-16h/day (4 sessions) M2-6: 1 day/ week physical therapist: exercises, skin care \& MLD, and self-management by patient and wearing compression garment 14-16h/day (20 sessions)~M7-12: 6 months of maintenance DLT by patient (self-management) and home physical therapist:~- 1 day/week physical therapist: skin care, MLD, exercises (26 sessions) Month 13-18: 6 months of maintenance DLT by patient Month 19-36: 18 months of follow-up

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstructive lymphatic surgery
Description: For the procedure of LVA:~- Aim: making anastomoses of lymph vessels at the capillary level with a diameter of 0.3 to 0.8 mm, to redirect lymph to venous stream directly~For the procedure of LNT:~- Aim:~1. Placed lymph nodes act as sponge to absorb lymphatic fluid and direct it into the vascular network;~2. Placed lymph nodes induce lymphangiogenesis
Study: NCT05981001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery for harvesting tumor-draining lymph nodes
Description: A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 60 mg/kg IV daily over approximately two hours for two days. Cyclophosphamide will be initiated seven days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: After administration of cyclophosphamide, fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes for five days, starting five days prior to LNL transfer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-draining lymph node-derived lymphocyte (LNL)
Description: In the dose-escalation portion of phase I study, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion of phase I study, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).~In the phase II study, participants receive single infusion of LNL at the RP2D.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab will be administered at a fixed dose of 200mg IV on Day 1 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: Camrelizumab will be administered at a fixed dose of 200mg IV on Day 1 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered at 100 mg/m\^2 IV on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study: NCT04246008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Description: The exercise training was developed based on assuring the correct performance of the exercise focusing in motor control.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional strength training
Description: The exercise training was developed based on standard strength training used in cardiac rehabiliation programmes